List of Neupro drug patents
Neupro is owned by Ucb Inc.
Neupro contains Rotigotine.
Neupro has a total of 6 drug patents out of which 0 drug patents have expired.
Neupro was authorised for market use on 09 May, 2007.
Neupro is available in film, extended release;transdermal dosage forms.
Neupro can be used as a method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient, treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system.
The generics of Neupro are possible to be released after 01 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(5 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(2 years from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(4 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(9 years from now) | |
Drugs and Companies using ROTIGOTINE ingredient
Market Authorisation Date: 09 May, 2007
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic